Results 251 to 260 of about 2,093,614 (359)
Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma
Molecular Oncology, EarlyView.PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga +2 more
wiley +1 more source
AAV-DJ-Mediated MYOC Silencing as a Gene Therapy Approach for Myocilin-Associated Glaucoma. [PDF]
Invest Ophthalmol Vis SciWan Y +7 more
europepmc +1 more source
Visual Tract Integrity before and after gene therapy in congenital Achromatopsia [PDF]
Abramovitch Hillel +6 more
openalex +1 more source
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Surgical Approaches to Retinal Gene Therapy: 2025 Update. [PDF]
Bioengineering (Basel)Patel MJ +4 more
europepmc +1 more source
Trial of magnetic resonance–guided putaminal gene therapy for advanced Parkinson's disease
, 2019 John D. Heiss +13 more
openalex +2 more sources
Molecular Oncology, EarlyView.Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee +8 more
wiley +1 more source